US 12,459,829 B2
Amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate
Sara Frykstrand Ångström, Uppsala (SE); Ottilia Arvén, Uppsala (SE); Tuulikki Lindmark, Uppsala (SE); and Peter Åsberg, Stockholm (SE)
Assigned to DISRUPTIVE PHARMA AB, Uppsala (SE)
Appl. No. 17/291,763
Filed by DISRUPTIVE PHARMA AB, Uppsala (SE)
PCT Filed Nov. 6, 2019, PCT No. PCT/SE2019/051114
§ 371(c)(1), (2) Date May 6, 2021,
PCT Pub. No. WO2020/096513, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/756,628, filed on Nov. 7, 2018.
Claims priority of application No. 1851383-8 (SE), filed on Nov. 7, 2018.
Prior Publication US 2022/0024777 A1, Jan. 27, 2022
Int. Cl. C01F 5/24 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C01F 5/02 (2006.01)
CPC C01F 5/24 (2013.01) [A61K 9/0053 (2013.01); A61K 45/06 (2013.01); C01F 5/02 (2013.01); C01P 2002/02 (2013.01); C01P 2004/61 (2013.01); C01P 2006/12 (2013.01); C01P 2006/14 (2013.01); C01P 2006/16 (2013.01)] 16 Claims
 
1. A solid amorphous pharmaceutical admixture comprising an active pharmaceutical ingredient (API) in combination with a particulate anhydrous mesoporous magnesium carbonate (MMC), wherein the API is sorafenib.